Exagen Inc. XGN Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Exagen Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Exagen Inc. (XGN) reported deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost of $596K in Q4 2025.
- How has Exagen Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost changed year-over-year?
- Exagen Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost decreased by 0.3% year-over-year, from $598K to $596K.
- What is the long-term trend for Exagen Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost?
- Over 5 years (2020 to 2025), Exagen Inc.'s deferred tax assets, tax deferred expense, compensation and benefits, share-based compensation cost has grown at a 2.5% compound annual growth rate (CAGR), from $528K to $596K.